Literature DB >> 15479820

Effects on rotavirus cell binding and infection of monomeric and polymeric peptides containing alpha2beta1 and alphaxbeta2 integrin ligand sequences.

Kate L Graham1, Weiguang Zeng, Yoshikazu Takada, David C Jackson, Barbara S Coulson.   

Abstract

Integrin-using rotaviruses bind MA104 cell surface alpha2beta1 integrin via the Asp-Gly-Glu (DGE) sequence in virus spike protein VP4 and interact with alphaxbeta2 integrin during cell entry through outer capsid protein VP7. Infection is inhibited by the alpha2beta1 ligand Asp-Gly-Glu-Ala (DGEA) and the alphaxbeta2 ligand Gly-Pro-Arg-Pro (GPRP), and virus-alpha2beta1 binding is increased by alpha2beta1 activation. In this study, we analyzed the effects of monomers and polymers containing DGEA-, GPRP-, and DGEA-related peptides on rotavirus binding and infection in intestinal (Caco-2) and kidney (MA104) cells and virus binding to recombinant alpha2beta1. Blockade of rotavirus-cell binding and infection by peptides and anti-alpha2 antibody showed that Caco-2 cell entry is dependent on virus binding to alpha2beta1 and interaction with alphaxbeta2. At up to 0.5 mM, monomeric DGEA and DGAA inhibited binding to alpha2beta1 and infection. At higher concentrations, DGEA and DGAA showed a reduced ability to inhibit virus-cell binding and infection that depended on virus binding to alpha2beta1 but occurred without alteration in cell surface expression of alpha2, beta2, or alphavbeta3 integrin. This loss of DGEA activity was abolished by genistein treatment and so was dependent on tyrosine kinase signaling. It is proposed that this signaling activated existing cell surface alpha2beta1 to increase virus-cell attachment and entry. Polymeric peptides containing DGEA and GPRP or GPRP only were inhibitory to SA11 infection at approximately 10-fold lower concentrations than peptide monomers. As polymerization can improve peptide inhibition of virus-receptor interactions, this approach could be useful in the development of inhibitors of receptor recognition by other viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479820      PMCID: PMC523290          DOI: 10.1128/JVI.78.21.11786-11797.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Mechanisms of integrin-mediated virus attachment and internalization process.

Authors:  K Triantafilou; Y Takada; M Triantafilou
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

2.  The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site.

Authors:  Philip R Dormitzer; Zhen-Yu J Sun; Gerhard Wagner; Stephen C Harrison
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

3.  Initial interaction of rotavirus strains with N-acetylneuraminic (sialic) acid residues on the cell surface correlates with VP4 genotype, not species of origin.

Authors:  Max Ciarlet; Juan E Ludert; Miren Iturriza-Gómara; Ferdinando Liprandi; James J Gray; Ulrich Desselberger; Mary K Estes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Expression and functional importance of collagen-binding integrins, alpha 1 beta 1 and alpha 2 beta 1, on virus-activated T cells.

Authors:  Susanne Ø Andreasen; Allan R Thomsen; Victor E Koteliansky; Tatiana I Novobrantseva; Andrew G Sprague; Antonin R de Fougerolles; Jan P Christensen
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

Review 5.  Integrins: bidirectional, allosteric signaling machines.

Authors:  Richard O Hynes
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

6.  Localization of membrane permeabilization and receptor binding sites on the VP4 hemagglutinin of rotavirus: implications for cell entry.

Authors:  M Tihova; K A Dryden; A R Bellamy; H B Greenberg; M Yeager
Journal:  J Mol Biol       Date:  2001-12-14       Impact factor: 5.469

7.  Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets.

Authors:  Hong Chen; Mark L Kahn
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

8.  Monkey rotavirus binding to alpha2beta1 integrin requires the alpha2 I domain and is facilitated by the homologous beta1 subunit.

Authors:  Sarah L Londrigan; Kate L Graham; Yoshikazu Takada; Peter Halasz; Barbara S Coulson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Integrin-using rotaviruses bind alpha2beta1 integrin alpha2 I domain via VP4 DGE sequence and recognize alphaXbeta2 and alphaVbeta3 by using VP7 during cell entry.

Authors:  Kate L Graham; Peter Halasz; Yan Tan; Marilyn J Hewish; Yoshikazu Takada; Erich R Mackow; Martyn K Robinson; Barbara S Coulson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation.

Authors:  K Sadler; W Zeng; D C Jackson
Journal:  J Pept Res       Date:  2002-09
View more
  10 in total

1.  Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry.

Authors:  Aravind Asokan; Julie B Hamra; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Richard J Samulski
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Rotavirus replication in intestinal cells differentially regulates integrin expression by a phosphatidylinositol 3-kinase-dependent pathway, resulting in increased cell adhesion and virus yield.

Authors:  Peter Halasz; Gavan Holloway; Stephen J Turner; Barbara S Coulson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

3.  Identification of Equine Lactadherin-derived Peptides That Inhibit Rotavirus Infection via Integrin Receptor Competition.

Authors:  Andrea Civra; Maria Gabriella Giuffrida; Manuela Donalisio; Lorenzo Napolitano; Yoshikazu Takada; Barbara S Coulson; Amedeo Conti; David Lembo
Journal:  J Biol Chem       Date:  2015-03-26       Impact factor: 5.157

4.  Relative roles of GM1 ganglioside, N-acylneuraminic acids, and α2β1 integrin in mediating rotavirus infection.

Authors:  Fiona E Fleming; Raphael Böhm; Vi T Dang; Gavan Holloway; Thomas Haselhorst; Paul D Madge; Jaigeeth Deveryshetty; Xing Yu; Helen Blanchard; Mark von Itzstein; Barbara S Coulson
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

5.  Determinants of the specificity of rotavirus interactions with the alpha2beta1 integrin.

Authors:  Fiona E Fleming; Kate L Graham; Yoshikazu Takada; Barbara S Coulson
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

6.  Synthesis and characterization of biodegradable HPMA-oligolysine copolymers for improved gene delivery.

Authors:  Rob S Burke; Suzie H Pun
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

7.  Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Authors:  Valeria Cagno; Manuela Donalisio; Andrea Civra; Marco Volante; Elena Veccelli; Pasqua Oreste; Marco Rusnati; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  Rotavirus infection of infant and young adult nonobese diabetic mice involves extraintestinal spread and delays diabetes onset.

Authors:  Kate L Graham; Joanne A O'Donnell; Yan Tan; Natalie Sanders; Emma M Carrington; Janette Allison; Barbara S Coulson
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

9.  Two dimensional VOPBA reveals laminin receptor (LAMR1) interaction with dengue virus serotypes 1, 2 and 3.

Authors:  Phaik Hooi Tio; Wan Wui Jong; Mary Jane Cardosa
Journal:  Virol J       Date:  2005-03-25       Impact factor: 4.099

10.  Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol.

Authors:  Andrea Civra; Valeria Cagno; Manuela Donalisio; Fiorella Biasi; Gabriella Leonarduzzi; Giuseppe Poli; David Lembo
Journal:  Sci Rep       Date:  2014-12-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.